VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

African horse sickness virus

Table of Contents
  1. General Information
    1. NCBI Taxonomy ID
  2. Vaccine Information
    1. ALVAC-AHSV
    2. rMVA- AHS-VP2
  3. References
I. General Information
1. NCBI Taxonomy ID:
40050
II. Vaccine Information
1. ALVAC-AHSV
a. Vaccine Ontology ID:
VO_0004725
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Preparation
Recombinant canarypox virus vector (ALVAC-AHSV) co-expressing synthetic genes encoding the outer capsid proteins (VP2 and VP5) of AHSV serotype 4 (AHSV-4) (Guthrie et al., 2009).
f. Immunization Route
Intramuscular injection (i.m.)
g. Horse Response
  • Vaccination Protocol: Two groups of four horses each (two males and two females) were inoculated intramuscularly with 107.1 or 106.4 TCID50, respectively, of ALVAC–AHSV in approximately 1 ml of diluent containing a Carbopol® 974P adjuvant (BF Goodrich) (Guthrie et al., 2009).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: All nine horses were challenged by intravenous inoculation of 105.5 TCID50 of AHSV-4 at 28 days after the second vaccination (week 8) (Guthrie et al., 2009).
  • Efficacy: Post challenge, all horses remained healthy and showed no adverse effects after vaccination (Guthrie et al., 2009).
2. rMVA- AHS-VP2
a. Vaccine Ontology ID:
VO_0004758
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Preparation
Recombinant vaccine based on modified vaccinia Ankara expressing AHS-4 VP2 (MVA-VP2) (Castillo-Olivares et al., 2011).
f. Immunization Route
Intramuscular injection (i.m.)
g. Mouse Response
  • Vaccination Protocol: The mice were vaccinated by the intra-peritoneal route on days 0 and 28 with 107 pfu of MVA-VP2 per mouse (Castillo-Olivares et al., 2011).
  • Vaccine Immune Response Type: VO_0000287
  • Challenge Protocol: The mice were subsequently challenged on day 35 with 106 pfu of AHSV-4 (Castillo-Olivares et al., 2011).
  • Efficacy: All of the MVA-VP2 vaccinated animals were also protected from clinical signs and were completely healthy until the end of the study period (Castillo-Olivares et al., 2011).
III. References
1. Castillo-Olivares et al., 2011: Castillo-Olivares J, Calvo-Pinilla E, Casanova I, Bachanek-Bankowska K, Chiam R, Maan S, Nieto JM, Ortego J, Mertens PP. A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model. PloS one. 2011; 6(1); e16503. [PubMed: 21298069].
2. Guthrie et al., 2009: Guthrie AJ, Quan M, Lourens CW, Audonnet JC, Minke JM, Yao J, He L, Nordgren R, Gardner IA, Maclachlan NJ. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus. Vaccine. 2009; 27(33); 4434-4438. [PubMed: 19490959].